ShowcaseBio analysis of Global Stem Cell research centres and publication trends over last 10 years

1. Benchmarking the Global Stem Cell Science Base
An objective and evidence based anlaysis

2. Better Evidence - Smarter Business
• Biolauncher extends the principals of bioinfirmatics to business
development
• Integrating extensive and diverse sources of commercial life science
information to make informed business decisions
• Proprietary Information System called ShowcaseBio
• 350 publically available data feeds
• Advanced text analytics
• Visualisation
• Brings together patent, publication, company, news and more
• An extensive range of business applications
• This case study illustrates how the system enables open innovation and evidenced
based partnering strategies

3. ShowcaseBio System
News Company Events & Directories & Scientific Drugs, Devices, Patents &
& Deals Websites Conferences Listings Literature Products & Services Inventions
Automated Semantic Semantic Database
Data Integration Processes
Market / Industry Targeted Sales Trip Supply Chain Purchasing & Open
Analysis Lead Generation Planner Management Partnering Innovation

4. Why Benchmark Cambridge, UK?
• Approached by regional inward investment agency – East of England
International
• Responsible for promoting Cambridge, UK as a destination for global life science
businesses
• Prioritising Stem cell science and regenerative medicine
• Wanted to understand “How good is Cambridge, UK?”
• Challenge of that question is you need to be able to answer “How good
is every other city in the world and where does Cambridge, UK rank?”
• Other centres are investing to attract stem cell business

5. Benchmarking Stem Cell Science
• Aim: To quantify Cambridge, UK stem cell research leadership
position
• Employ objective methodology that examines academic output
• Analysis performed using ShowcaseBio
• Considered peer review publications (academic output) recorded in
PubMed
• with MeSH heading of „Stem Cells‟
• Papers published between 2000 and 2009
• Divided into annual datasets
• Attributed and mapped total publications per city based upon first
author address

6. Total Number of Stem Cell Papers 2009

7. Total Publications Shows Capacity
• Each publication is not equivalent – some greatly advance the
understanding of the field, others are additive
• Biolauncher can not read each paper, nor are we qualified to make
judgements about each publications merits
• Employ Impact factors to rank publications by impact
• Used EigenFactor Article Influence™
• Article Influence score is a measure of the average influence of each of its
articles over the first five years after publication
• More information at www.eigenfactor.org
• Comparable to Thomson Scientific's widely-used Impact Factor
• Map the total impact factor by city to reveal total competence at each
location

8. Total Impact Factor – Competence

9. Total Impact Factor
• Total Impact Factor is a measure of capacity and competence at each
location.
• It does not reveal academic leadership, because
• Relatively few leaders in any subject
• Leadership is identified by the
• The prestige/impact of the journal that publishes papers
• Frequency that the publication is cited by peers
• Leaders have a higher average impact score than their peers
• Biolauncher calculated and mapped the average impact factor for the
top 15 cities for each year 2000-2009

10. Avg. Impact Factor - Leadership

11. Top 15 Stem Cell Centres
7
6
Ann Arbor, US
Baltimore, US
5
Average Impact Factor
Bethesda, US
Boston, US
Cambridge, US
4 Cambridge, GB
Houston, US
London, GB
3 Los Angeles, US
New York, US
Paris, FR
2 Philadelphia, US
San Francisco, US
Stanford, US
1 Tokyo, JP
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009

12. Conclusions
• Cambridge scientists are publishing influential research
• Cambridge and London leading location for research in Europe,
combining leadership and capacity
• Cambridge, UK as an important open innovation destination for
companies seeking to access stem cell innovation
• Methodology provides an objective approach to assessing academic
leadership in any life science domain

13. Limitations of the Analysis
• Affiliation information is usually only associated with the first author of
a paper. For collaborative papers with multiple authors at different
insitutions this may mean that some attributions are missed.
• All average impact factors are fundamentally based on citation
metrics within a large but finite pool of publications, the majority of
which are English language journals. This inevitably discriminates
against papers that are written in languages other than English.
• Not all addresses provided in PubMed will geocode correctly.
Badly
formed or incomplete addresses may be excluded from this analysis.
• BioLauncher chose not to aggregate closely related place names, e.g.
Stanford and Palo Alto ; Cambridge and Boston, US or Cambridge
and London, UK.

14. Commercial Strategy Applications
Service or Characterise
Review
Technology Target Refine Query Act!
Results
Offered/Wanted Businesses
• Planning market entry strategy, licensing partner or investor exit
• Review clinical trials to understand product development potential
• Choosing an overseas location – consider direct flight destinations
from the nearest airport - can you reach customers easily?
• Best results arise from being able to consider a wide range of
information
• Expect to review results to effectively prioritise opportunity

15. Connections to European Biologics Market
Grey discs show a 50
mile radius around
airports served by
Stansted London Stansted –
Airport 30 minutes from
Cambridge, UK

16. Case Study: Finding Licensing Deals
Service or
Technology Marketing division seeking high value diagnostic imaging products to launch in Far East
Offered/Wanted
Characterise Modality specific, CE marked/FDA approved with diagnostic application to Liver, Abdomen,
Target Businesses Breast, Point of Care, Emergency Room without access to Far Eastern Market
Expanded query terms to look for relevant terms,
Refine Query 527,075 pages
using text analytics and vocabulary tools in ShowcaseBio
over 41,500
companies
Review Identified a due diligence set of 230 companies for review,
Results grouped by diagnostic indication(s) and stage of clinical approval
Act! Prioritised 8 companies as a shortlist for consideration.

17. Find out more...
• Visit our website biolauncher.com
• Examine our track record http://biolauncher.com/track-record/
• Meet the team http://biolauncher.com/about/
• And contact us, our contact information is here
http://biolauncher.com/contact/ and it costs nothing to talk!